Skip to main content
HCPCS J2353 · Level II · Part B drug

J2353: octreotide (Sandostatin Lar Depot), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J2353

Billing unit
1 MG
Octreotide injection, depot
ASP payment limit
$211.321
October 2026; +1.6% vs July 2026
Practitioner MUE
60
MAI 3
OPPS status
SI K
APC 1207
NCCI exposure
no PTP pairs
Coverage articles
1
7 states

TL;DR

HCPCS J2353 is the Level II code for Injection, octreotide, depot form for intramuscular injection, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $211.321 per billing unit, up 1.6% from July 2026. The practitioner MUE allows up to 60 units per date of service (MAI 3), so a full 60-unit day is $12,679.26 at the current limit. Under OPPS it carries status indicator K in APC 1207. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names octreotide: J2354 (intravenous and subcutaneous route; billed per 25 mcg). The ASP crosswalk maps 9 NDCs to it, sold as Sandostatin Lar Depot, Octreotide Acetate by Novartis Pharmaceuticals Corporation, Teva Pharmaceuticals USA, Inc., Mylan Institutional LLC. 1 Medicare coverage article lists the code across 7 states, including A56531.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J2353 at $211.321 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $208.095 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J2353
QuarterPayment limitPerCoinsurance
October 2026$211.3211 MG20%
July 2026$208.0951 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 9 NDCs from 3 labelers to J2353. Report the NDC in the claim's drug segment and bill the number of J2353 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J2353
NDCDrug nameLabelerPackage sizeBilling units / package
00078-0811-81Sandostatin Lar DepotNovartis Pharmaceuticals Corporation1 × 110
00078-0818-81Sandostatin Lar DepotNovartis Pharmaceuticals Corporation1 × 120
00078-0825-81Sandostatin Lar DepotNovartis Pharmaceuticals Corporation1 × 130
00480-9257-08Octreotide AcetateTeva Pharmaceuticals USA, Inc.1 × 110
00480-9259-08Octreotide AcetateTeva Pharmaceuticals USA, Inc.1 × 120
00480-9262-08Octreotide AcetateTeva Pharmaceuticals USA, Inc.1 × 130
67457-0756-10Octreotide AcetateMylan Institutional LLC1 × 110
67457-0759-20Octreotide AcetateMylan Institutional LLC1 × 120
67457-0762-30Octreotide AcetateMylan Institutional LLC1 × 130

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J2353. For practitioners the limit is 60 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J2353 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services603 Date of Service Edit: ClinicalClinical: Society Comment
Facility outpatient hospital603 Date of Service Edit: ClinicalClinical: Society Comment
DME supplier03 Date of Service Edit: ClinicalCMS Policy

MUE for J2353 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J2353 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J2353 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J2353 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists J2353 in their HCPCS tables, covering 7 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J2353
ArticleTitleContractor(s)StatesRelated LCD
A56531Billing and Coding: Octreotide Acetate for Injectable Suspension (Sandostatin® LAR Depot)Palmetto GBAAL GA NC SC TN VA WVL33438

Diagnoses Medicare contractors cover for J2353

One billing and coding article attaches a covered diagnosis list to J2353: 72 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for J2353
ICD-10-CMDescription (FY2027)Articles covering
C7A.010Malignant carcinoid tumor of the duodenum1 of 1
C7A.011Malignant carcinoid tumor of the jejunum1 of 1
C7A.012Malignant carcinoid tumor of the ileum1 of 1
C7A.019Malignant carcinoid tumor of the small intestine, unspecified portion1 of 1
C7A.020Malignant carcinoid tumor of the appendix1 of 1
C7A.021Malignant carcinoid tumor of the cecum1 of 1
C7A.022Malignant carcinoid tumor of the ascending colon1 of 1
C7A.023Malignant carcinoid tumor of the transverse colon1 of 1
C7A.024Malignant carcinoid tumor of the descending colon1 of 1
C7A.025Malignant carcinoid tumor of the sigmoid colon1 of 1
C7A.026Malignant carcinoid tumor of the rectum1 of 1
C7A.029Malignant carcinoid tumor of the large intestine, unspecified portion1 of 1
C7A.090Malignant carcinoid tumor of the bronchus and lung1 of 1
C7A.091Malignant carcinoid tumor of the thymus1 of 1
C7A.092Malignant carcinoid tumor of the stomach1 of 1
57 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J2353 are counted here. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J2353, by article
ArticleContractorGroups that applyCovered codes for J2353Full list
A56531Palmetto GBAone list for every code in the article72On LCD L33438

Local coverage policies that list J2353

1 active Local Coverage Determination lists J2353 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J2353 carries status indicator K and is assigned to APC 1207, with a published national unadjusted payment of $211.321. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J2353 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $211.32 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J2353 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J2353

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J2353

What does HCPCS code J2353 describe?

J2353 is defined by CMS as "Injection, octreotide, depot form for intramuscular injection, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J2353 a CPT code?

No. J2353 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as octreotide (Sandostatin Lar Depot); CPT codes are five-character codes maintained by the AMA. On a Part B claim J2353 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J2353 in October 2026?

The ASP-based payment limit is $211.321 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $208.095. Commercial payers use their own fee schedules.

How many units of J2353 can be billed per day?

The practitioner Medically Unlikely Edit is 60 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Clinical: Society Comment" as the rationale.

Which NDCs map to J2353?

The October 2026 ASP crosswalk lists 9 NDCs from 3 labelers: Sandostatin Lar Depot (Novartis Pharmaceuticals Corporation); Octreotide Acetate (Teva Pharmaceuticals USA, Inc.); Octreotide Acetate (Mylan Institutional LLC). For example NDC 00078-0811-81 (package size 1) equals 10 billing units of J2353.

Does J2353 have NCCI bundling edits?

No active practitioner PTP pairs list J2353 as a column-1 or column-2 code in the v323r0 release.

J2353 vs J2354: what is the difference?

Both are HCPCS Level II codes whose descriptor names octreotide. What sets J2354 apart: intravenous and subcutaneous route; billed per 25 mcg. J2353 is billed per 1 mg, limit $211.321, MUE 60; J2354 is billed per 25 mcg, limit $0.574, MUE 60. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention J2353?

1 current Billing and Coding Article in the Medicare Coverage Database lists J2353, covering 7 states: A56531 (Billing and Coding: Octreotide Acetate for Injectable Suspension (Sandostatin® LAR Depot)).

What diagnosis codes support J2353?

One Medicare billing and coding article lists 72 covered ICD-10-CM codes for J2353, for example C7A.010 (Malignant carcinoid tumor of the duodenum); C7A.011 (Malignant carcinoid tumor of the jejunum); C7A.012 (Malignant carcinoid tumor of the ileum); C7A.019 (Malignant carcinoid tumor of the small intestine, unspecified portion); C7A.020 (Malignant carcinoid tumor of the appendix). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.